As our preliminary experiments indicated that aGalCer provides a much stronger stimulus of CD4+ T cell proliferation than C16:0 and C24:0, we injected higher doses (50 mg/dose or 100 mg/dose) of C16:0 and C24:0 into NOD mice according to the same multi-dose protocol and still found that these higher doses provided only very low (10–20%) protection of the mice from the spontaneous development of T1D. This evidence concerns the gene CD4 and type 1 diabetes mellitus.